# SMARCA4/2 Inhibitor for POU2F3-Positive SCLC

> **NCT07551635** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 20 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** FHD-286

## Key facts

- **NCT ID:** NCT07551635
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-04
- **Primary completion:** 2028-01-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07551635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07551635, "SMARCA4/2 Inhibitor for POU2F3-Positive SCLC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07551635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*